Cargando…

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis

Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR-1) on platelets. It inhibits thrombin-induced platelet activation by binding to the ectodomain of PAR-1. After animal studies and Phase II studies showed that vorapa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diehl, Philipp, Bode, Christoph, Duerschmied, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529257/ https://www.ncbi.nlm.nih.gov/pubmed/26346960 http://dx.doi.org/10.2147/TCRM.S55469

Ejemplares similares

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Serotonin: a platelet hormone modulating cardiovascular disease
por: Rieder, Marina, et al.
Publicado: (2020)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
por: Skelley, Jessica W, et al.
Publicado: (2018)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell, Rebecca, et al.
Publicado: (2019)

Potential Mechanisms Linking Atherosclerosis and Increased Cardiovascular Risk in COPD: Focus On Sirtuins
por: Corbi, Graziamaria, et al.
Publicado: (2013)

Platelet Contributions to Myocardial Ischemia/Reperfusion Injury
por: Schanze, Nancy, et al.
Publicado: (2019)

The Effects of Serotonin in Immune Cells
por: Herr, Nadine, et al.
Publicado: (2017)

Procedural justice and egalitarian principles for rationing decisions in the COVID-19 crisis
por: Supady, Alexander, et al.
Publicado: (2020)

Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
por: Kim, Nam Hoon, et al.
Publicado: (2020)

The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases
por: Wójcik-Cichy, Kamila, et al.
Publicado: (2018)

From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
por: Poznyak, Anastasia V., et al.
Publicado: (2022)

Extracellular Vesicles Are Associated With Outcome in Veno-Arterial Extracorporeal Membrane Oxygenation and Myocardial Infarction
por: Siegel, Patrick M., et al.
Publicado: (2021)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019)

Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease
por: Blachut, Dominika, et al.
Publicado: (2023)

Lipid Biomarkers and Atherosclerosis—Old and New in Cardiovascular Risk in Childhood
por: Močnik, Mirjam, et al.
Publicado: (2023)

Immunity, atherosclerosis and cardiovascular disease
por: Frostegård, Johan
Publicado: (2013)

Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19
por: Supady, Alexander, et al.
Publicado: (2020)

Concept of Atherosclerosis Velocity: Is It a Better Measure of Cardiovascular Risk?
por: Kazemi-Bajestani, Seyyed Mohammad Reza, et al.
Publicado: (2013)

Cytokine Adsorption in Critically Ill Patients Requiring ECMO Support
por: Lother, Achim, et al.
Publicado: (2019)

Extracorporeal membrane oxygenation in Pneumocystis jirovecii pneumonia: outcome in HIV and non-HIV patients
por: Rilinger, Jonathan, et al.
Publicado: (2019)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rskaur3c3ec3l82svoi88pkhum